Skip to main content
. 2021 Jul 13;11(3):217–233. doi: 10.1007/s13534-021-00199-4

Fig. 12.

Fig. 12

a Schematic illustration of the SEHPA (SE@HMSN/P-Apt: Sora- and pEGFR-loaded HMNS/PAMAM-Aptamer) nanoparticle preparation. b The downregulation of EGFR/PI3K/Akt pathway is caused by the synergistic effects of Sora and pEGFR in SEHPA NPs. c SEHPA nanoparticles inhibited the growth of tumor, indicating a successful anticancer effect. Reprinted with permission from American Chemical Society [106]